

CALL FOR EXPRESSIONS OF INTEREST (EOI)

Invitation to submit an Expression of Interest for the supply and delivery of PEN-Plus commodities to Republic of Liberia

Reference	EOI/CHAI-LBR-PENPLUS-001/26
Issued by	Clinton Health Access Initiative (CHAI)
Issue date	13 October 2026
Closing date	27 October 2026, 23:59 GMT
Submissions & queries	ncdprocurement@clintonhealthaccess.org (subject line: quote reference EOI/CHAI-LBR-PENPLUS-001/26 and your organization name)
Delivery terms	CIP — Roberts International Airport, Monrovia, Liberia (Incoterms® 2020)

List of Abbreviations

Abbreviation	Meaning
CHAI	Clinton Health Access Initiative
CMS	Central Medical Store
HMIS	Health Management Information System
NCD	Non-Communicable Disease
NCDI	Non-Communicable Diseases and Injuries
LMIC	Low- and Middle-Income Country
PEN-Plus	Package of Essential NCD interventions – Plus
T1D / SCD / CVD	Type 1 Diabetes / Sickle Cell Disease / Cardiovascular Disease
EOI / RFQ	Expression of Interest / Request for Quotation
QA	Quality Assurance
QMS	Quality Management System
SOP	Standard Operating Procedure
MQAS	Model Quality Assurance System (WHO)
SRA	Stringent Regulatory Authority
WHO	World Health Organization
LMHRA	Liberia Medicines and Health Products Regulatory Authority
GMP	Good Manufacturing Practice
ISO 13485	Medical-device QMS standard
CE / US-FDA	European Conformity marking / US Food & Drug Administration authorization
CIP	Carriage and Insurance Paid To (Incoterms® 2020)

Disclaimer Notice and Confidentiality

This Expression of Interest (EOI) is issued by the Clinton Health Access Initiative (CHAI) in connection with procurement of quality-assured PEN-Plus commodities (medicines, diagnostics, devices, and consumables) to support the scale-up of PEN-Plus services at first-referral hospitals in Liberia. **This EOI is issued for planning and pre-qualification purposes and is not a Call for Proposals, a Request for Tender, or an offer to contract. CHAI reserves the right to determine the final list of prequalified vendors based on information received through this process, and assessment conducted at its own discretion.**

Any information submitted is provided voluntarily and may be used by CHAI, and — on a need-to-know basis — by designated program partners (collectively, the “Evaluation Team”), solely to assess market capabilities, inform planning, and design or conduct this and any related solicitation. **Neither CHAI nor any program partner is under any obligation to procure any goods or services described herein.**

Confidentiality. Respondents should clearly mark any information they consider confidential. The Evaluation Team will take reasonable measures to keep such information confidential and will not share it outside the Evaluation Team without written authorization, except information that: (a) was known prior to disclosure; (b) is or becomes public without breach; (c) is received from a third party without breach; or (d) is independently developed without use of the confidential information. Information not marked confidential will not be shared outside the Evaluation Team without authorization unless anonymized or aggregated.

1. Background & Objective

Clinton Health Access Initiative (CHAI) is supporting expansion of the PEN-Plus model in Liberia to strengthen screening, diagnosis, treatment, and follow-up for severe chronic NCDs, including type 1 diabetes, cardiovascular disease, chronic kidney disease, liver disease, sickle cell disease, and respiratory disease, at first-level referral hospitals. Building on lessons from Liberia’s first PEN-Plus pilot site, CHAI is supporting expansion of the PEN-Plus model and its integration into national systems.

Liberia’s NCD burden is significant and rising. Between 2019 and 2023, the national HMIS recorded ~49,800 NCD cases and ~5,050 related deaths, with cardiovascular disease the leading cause. Diabetes affects ~3% of the population (with under-diagnosis likely), and T1D outcomes are particularly poor without consistent access to insulin, diagnostics, and follow-up care. The National NCDI Policy and Strategic Plan (validated in 2025) identifies PEN-Plus scale-up as a priority.

CHAI brings extensive experience structuring transparent, competitive sourcing for quality-assured health commodities in Liberia and other low- and middle-income countries (LMICs). Combining global market expertise with in-country execution, CHAI has delivered large multi-country procurements — including oxygen and NCD commodities — achieving meaningful price and lead-time efficiencies.

The purpose of this Expression of Interest (EOI) is to pre-qualify manufacturers and authorized distributors capable of reliably supplying quality-assured PEN-Plus commodities to Liberia. Respondents must demonstrate that they meet the minimum eligibility, quality assurance and compliance requirements, and information collected will be used to shortlist vendors, who will then be invited to respond to a RFQ.

2. Scope of Interest (Commodity Groups)

CHAI seeks to pre-qualify vendors able to supply the PEN-Plus commodities required for this project. Products are grouped into four lots by category and handling requirement, as summarized in the table below, and an itemized product list is provided in the accompanying EOI Response Form (“Product Offer (Indicative)” tab). Respondents are encouraged to offer as many products as possible, both within each lot and across all lots for which they are qualified. At the RFQ stage, CHAI intends to solicit bids for the complete basket of goods listed in the Response Form. Any quantities shown in the Response Form are estimates for planning purposes only; firm quantities will be indicated at the RFQ stage.

Lot	Category	Handling	Conditions served
1	Oral and enteral medicines (solid-dose and liquid)	Ambient (+15 to +25 °C)	SCD, T1D, Kidney, CVD, Liver
2	Injectables & IV fluids	Ambient (+15 to +25 °C)	T1D, SCD, CVD
3	Inhalers (pressurized metered dose)	Ambient (+15 to +25 °C)	Respiratory

Lot	Category	Handling	Conditions served
4	Point-of-care diagnostics	Ambient / per manufacturer	T1D, Kidney

3. Minimum Eligibility, Quality & Compliance Requirements

3.1 Eligibility

- Legally registered manufacturer or manufacturer-authorized distributor.
- Ability and commitment to supply one or more products and to deliver on CIP terms to Roberts International Airport, Monrovia terms, with a maximum lead time not exceeding 12 weeks (84 calendar days) from issue of Purchase Order, and at least 75% of total product shelf life remaining at the time of delivery to Roberts International Airport.
- Products registered with the Liberia Medicines and Health Products Regulatory Authority (LMHRA) or willingness to register through a waiver process.

3.2 Quality Assurance

Vendors and products are expected to adhere to CHAI's Drug and Device Quality Policy, including to host or undergo a QA audit if engaged in coordination with CHAI. This includes WHO Prequalification and/or Stringent Regulatory Authority (SRA) approval where applicable (for medicines), ISO 13485, CE mark and/or US-FDA authorization (or equivalent) (for diagnostics and devices), and manufacture under current GMP.

3.3 Compliance

Compliance and business integrity requirements:

- Valid business registration and licensing: certificate of incorporation/registration; importer-exporter code; tax registration; and a valid wholesale/distribution drug license (or equivalent) for the country of operation.
- Organizational quality certification (e.g., ISO 9001) covering procurement, warehousing, and distribution, where held.
- Standard Operating Procedures (SOPs) for quality assurance and procurement. Where SOPs cannot be shared for confidentiality reasons, respondents must be willing to complete a documentation walkthrough and/or a remote (MQAS-style) quality audit.
- For authorized distributors: a Letter of Authorization / distributor agreement evidencing authorization from the manufacturer(s) of the products offered.
- Experience supplying the relevant product categories at commercial scale into LMICs (preferably for supply to Liberia or West Africa, including to comparable global health organizations), evidenced by at least three verifiable past-performance references (named organizations with contact details).

4. Terms and Conditions

Ethical Conduct and Conflicts of Interest: In accordance with CHAI's Global Code of Conduct and Conflict of Interest policy, CHAI is committed to conducting procurements with integrity and objectively selecting suppliers and vendors. CHAI maintains a zero-tolerance policy for acts including but not limited to collusion among vendors, submitting falsified bids, bribery, and/or other forms of fraud. Vendors engaging in such conduct will be disqualified from current and future opportunities. CHAI employees and others acting on CHAI's behalf are prohibited from accepting or asking for bribes, gifts, fees, or any other object of value or compensation related to doing business. Please contact ethics@clintonhealthaccess.org with any questions or concerns or to report any violations, or the CHAI Whistleblower Hotline at chai@integritycounts.ca (+1 866-921-6714 [Toll-Free U.S.] or +1 604-922-5953 [International]).

5. Instructions to Interested Parties

5.1 What to submit

Three components are mandatory; an EOI will not be considered if any is missing:

- **Signed Cover Letter** — summarizing the proposed solution, any support needed to meet requirements, and a statement of commitment to engage in the subsequent RFQ.
- **Completed EOI Response Form** (PEN-Plus_EOI_Response_Form_Liberia.xlsx) — company information, prior experience, and item-level details, signed on the “Instructions & Declaration” tab.
- **Attachments** as indicated in the EOI Response Form.

5.2 Timelines

Milestone	Date / window
EOI published	13 October 2026
Q&A period	From publication to 20 October 2026; consolidated answers shared with all respondents
Q&A deadline	20 October 2026
EOI closes	27 October 2026, 23:59 GMT — late submissions not accepted
Shortlist & RFQ invitations	Within 2 weeks of closing

5.3 Submission & queries

- By email only to ncdprocurement@clintonhealthaccess.org, quoting reference EOI/CHAI-LBR-PENPLUS-001/26 and your organization name in the subject line. Submissions must be in English and signed by a duly authorized representative.
- Questions must be emailed to the same inbox by the Q&A deadline; responses may be consolidated and shared with all respondents.
- All costs of preparing and submitting an EOI are borne by the respondent.
- CHAI may verify any information or reference provided and may amend or cancel this EOI by notice through the same channel.
- This EOI does not commit CHAI to shortlist any respondent or to proceed to an RFQ and creates no obligation or liability.
- Information relating to examination, clarification, and evaluation will not be disclosed to parties not officially concerned with the process.
- Late submissions resulting from documented email delivery failure will be considered at CHAI’s discretion; respondents should allow sufficient time before the deadline.